期刊文献+

敌敌畏对大鼠乙酰胆碱酯酶抑制作用的基准剂量和未观察到有害作用水平比较 被引量:1

Comparison of dichlorvos' s BMD and NOAEL in inhibition effect of acetylcholinesterase in rats
原文传递
导出
摘要 目的比较敌敌畏对大鼠乙酰胆碱酯酶抑制作用的基准剂量(BMD)和未观察到有害作用水平(NOAEL)。方法将80只健康清洁级成年雌性sD大鼠按体重随机分为8组,分别为对照(蒸馏水)组和0.22、0.44、0.88、1.75、3.50、7.00、14.00111g/kg敌敌畏染毒组,采用灌胃方式进行染毒,染毒容量为10ml/kg,每天1次,连续染毒21d。测定大鼠脑组织海马、皮质和血清中的乙酰胆碱酯酶活力,并计算BMD值和NOAEL值。结果与对照组比较,7.00~14.00mg/kg敌敌畏染毒组大鼠脑组织海马和3.50~14.00mg/kg敌敌畏染毒组大鼠脑组织皮质及1.75~14.00mg/kg敌敌畏染毒组大鼠血清中的乙酰胆碱酯酶活力均下降,差异有统计学意义(P〈0.05);且大鼠血清乙酰胆碱酯酶活力随敌敌畏染毒剂量的升高而下降。敌敌畏经口灌胃对大鼠脑组织皮质、海马和血清的BMD分别为1.80、0.81、0.51mg/kg,95%可信区间下限(BMDL)分别为1.42、0.44、0.30mg/kg;NOAEL分别为3.5、1.75、0.88mg/kg。结论BMD法比NOAEL法得到的安全参考剂量更为保守,能为人群提供更广泛的保护。 Objective To compare dichlorvos's BMD and NOAEL in the inhibition effect of aeetylcholinesterase in rats. Methods A total of 80 adult female SD rats were randomly divided into eight groups,one control group (distilled water) and seven dose groups (0.22,0.44,0.88,1.75,3.50,7.00 and 14.00 mg/kg body weight). After exposure through oral garage with 10 ml/kg for 21 consecutive days, acetylcholinesterase activities in the rat hippocampus,cortex and serum were determined,and the BMD values and NOAEL values were calculated. Results Compared with the control group, activity of acetylcholinesterase in hippocampal tissue, cortex and serum significantly decreased with a dose-dependent manner in the following groups, including dichlorvos exposure groups with the concentrations of 7.00-14.00 mg/kg, 3.50-14.00 mg/kg and 1.75-14.00 mg/kg. Calculated BMD values were 1.80,0.81,0.51 mg/kg,BMDL values were 1.42,0.44 and 0.30 mg/kg,NOAEL values were 3.50, 1.75 and 0.88 mg/kg. Conclusion The BMD method recommended a more conservative safe conference dose than the NOAEL method, which can provide protection for general population.
出处 《环境与健康杂志》 CAS CSCD 北大核心 2013年第6期486-489,共4页 Journal of Environment and Health
基金 国家自然科学基金(81072304)
关键词 基准剂量 乙酰胆碱酯酶 敌敌畏 风险评估 Benchmark dose Acetylcholinesterase Dichlorvos Risk assessment
  • 相关文献

参考文献14

  • 1Ishmael J, Macgregor JA, Manley A.Dichlorvos -a comprehensivereview of 11 rodent carcinogenicity studies [J].Regul Toxicol Pharm,2006, 44:238-248.
  • 2YangJ, Wang H,Xu W.Metabolomic analysis of rat plasma followingchronic low -dose exposure to dichlorvos [J].Hum Exp Toxicol,2013,32:196-205.
  • 3JeanR,Jefferson F,Martin DH.A health risk benchmark for theneurologic effects of styrene :comparison with NOAEL/LOAELapproach[J].Risk Analysis,2001,21 :117-126.
  • 4邹志方,靳峰,陈晓琴,李伯灵,赵新华,黄奕祥,陈少贤.儿童尿氟与骨质疏松相关性及尿氟基准剂量研究[J].环境与健康杂志,2012,29(7):627-629. 被引量:8
  • 5Crump K.A new method for determining allowable daily intakes [J].Fundam Appl Toxicol,1984,4 :854-871.
  • 6Kristi K,Dietrich VR,Salomon S.Comparing experimental designs forbenchmark dose calculations for continuous endpoints [J].RiskAnalysis,2006,26:1031 -1043.
  • 7Lorenz RR.Seeking optimal design for animal bioassay studies [J].Toxicol Sci, 2005,84 :1-3.
  • 8Gephart LA,SaIminen WF,NicoIich MJ.Evaluation of subchronic-toxicity data using the benchmark dose approach [J].Regul ToxicolPharm,2001,33:37-59.
  • 9Foster P, Auton T.Application of benchmark dose risk assessmentmethodology to developmental toxicity:an industrial view [J].ToxicolLett, 1995,82-83:555-559.
  • 10Budtz-Jorgensen E, Keiding N, Grandjean P.Benchmark dose calculationfrom epidemiological data[J].Biometrics,2001,57:698-706.

二级参考文献84

  • 1李颖,薛寿征.化学物致畸作用阈值判断──兼论烯效唑的致畸测试结果与ADI的拟订[J].癌变.畸变.突变,1996,8(1):14-17. 被引量:6
  • 2钱海雷,向全永,陈连生,金泰廙.基准剂量在氟接触人群骨效应评价中的应用[J].环境与职业医学,2007,24(1):12-15. 被引量:14
  • 3McCLELIAN R. Human health risk assessment: A historical overview and alternative paths forward[ J]. Inhal Toxicol, 1999, 11:477-518.
  • 4CRUMP K S. A new method for determining allowable daily intakes [ J ]. Fundam Appl Toxicol, 1984,4 (5) : 854-871.
  • 5EPA. The use of the benchmark dose approach in health risk assessment [ EB/OL]. [ 1995-06-10 ]. http://www, epa. gov/ raf/publications/pdfs/benehmark, pdf.
  • 6SAND S, FALK FILIPSSON A, VICTORIN K. Evaluation of the benchmark dose method for dichotomous data: model dependence and model selection [ J ]. Regul Toxicol Pharmacol, 2002,36: 184-197.
  • 7FOWLES J R, ALEXEEFF G V, DODGE D. The use of benchmark dose methodology with acute inhalation lethality data [ J]. Regul Toxicol Pharmacol, 1999,29:262-278.
  • 8EFSA. Opinion of the scientific panel on contaminants in the food chain on a request from the commission related to the potential increase of consumer health risk by a possible increase of the existing maximum levels for aflatoxins in almonds, hazelnuts and pistachios and derived products [ J]. EFSA ,2007,446 : 1-127.
  • 9SAND S,von ROSEN D, VICTORIN K,et al. Identification of a critical dose level for risk assessment : developments in benchmark dose analysis of continuous endpoints [ J ]. Toxicol Sci, 2006, 90:241-251.
  • 10AUTON T R. Calculation of benchmark doses from teratology data [ J]. Regul Toxicol Pharmacol, 1994,19 : 152-167.

共引文献28

同被引文献17

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部